TW201012489A - Encapsulation of biologically active agents - Google Patents

Encapsulation of biologically active agents Download PDF

Info

Publication number
TW201012489A
TW201012489A TW098114853A TW98114853A TW201012489A TW 201012489 A TW201012489 A TW 201012489A TW 098114853 A TW098114853 A TW 098114853A TW 98114853 A TW98114853 A TW 98114853A TW 201012489 A TW201012489 A TW 201012489A
Authority
TW
Taiwan
Prior art keywords
dab
ser
hip
val
nanoparticles
Prior art date
Application number
TW098114853A
Other languages
English (en)
Chinese (zh)
Inventor
Mehmet Fidanboylu
Irene Papanicolaou
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40944671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW201012489(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of TW201012489A publication Critical patent/TW201012489A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
TW098114853A 2008-05-06 2009-05-05 Encapsulation of biologically active agents TW201012489A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5077508P 2008-05-06 2008-05-06
US7417108P 2008-06-20 2008-06-20

Publications (1)

Publication Number Publication Date
TW201012489A true TW201012489A (en) 2010-04-01

Family

ID=40944671

Family Applications (4)

Application Number Title Priority Date Filing Date
TW098114853A TW201012489A (en) 2008-05-06 2009-05-05 Encapsulation of biologically active agents
TW098114851A TW201012488A (en) 2008-05-06 2009-05-05 Encapsulation of biologically active agents
TW098114867A TW201006495A (en) 2008-05-06 2009-05-05 Encapsulation of biologically active agents
TW098114865A TW201012490A (en) 2008-05-06 2009-05-05 Encapsulation of biologically active agents

Family Applications After (3)

Application Number Title Priority Date Filing Date
TW098114851A TW201012488A (en) 2008-05-06 2009-05-05 Encapsulation of biologically active agents
TW098114867A TW201006495A (en) 2008-05-06 2009-05-05 Encapsulation of biologically active agents
TW098114865A TW201012490A (en) 2008-05-06 2009-05-05 Encapsulation of biologically active agents

Country Status (11)

Country Link
US (1) US20110064821A1 (https=)
EP (2) EP2441447A1 (https=)
JP (1) JP2011522792A (https=)
KR (3) KR20110010760A (https=)
AR (4) AR071633A1 (https=)
CA (1) CA2721241A1 (https=)
CL (4) CL2009001081A1 (https=)
PE (4) PE20091829A1 (https=)
TW (4) TW201012489A (https=)
UY (4) UY31807A (https=)
WO (1) WO2009135853A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110064819A1 (en) * 2008-05-06 2011-03-17 Andrew Beaton Encapsulation of biologically active agents
WO2013021353A1 (en) 2011-08-11 2013-02-14 Bar-Ilan University Surface modified proteinaceous spherical particles and uses thereof
US10112987B2 (en) * 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
JP6612333B2 (ja) * 2014-05-30 2019-11-27 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 高薬物負荷ポリ（アルキル２−シアノアクリレート）ナノカプセル
WO2015181344A1 (en) * 2014-05-30 2015-12-03 AbbVie Deutschland GmbH & Co. KG Nanoencapsulation of antigen-binding molecules
EP3984525A1 (en) * 2014-06-12 2022-04-20 Adare Pharmaceuticals USA, Inc. Extended-release drug delivery compositions
JP6554493B2 (ja) 2014-06-24 2019-07-31 ザ・トラスティーズ・オブ・プリンストン・ユニバーシティＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｐｒｉｎｃｅｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 可溶性生物製剤、治療薬およびイメージング剤をカプセル化するためのプロセス
WO2019055539A1 (en) 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
US12357582B2 (en) * 2017-11-03 2025-07-15 The Trustees Of Princeton University Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations
US12186436B2 (en) 2018-07-19 2025-01-07 The Trustees Of Princeton University Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
WO2020056323A1 (en) * 2018-09-13 2020-03-19 The Brigham And Women's Hospital, Inc. Nanoparticle formulations and methods of their use
US20200147032A1 (en) 2018-11-14 2020-05-14 Robert K. Prud'homme Dihydromyricetin hot melt extrusion formulations and methods for forming them

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833666A (en) 1986-12-24 1989-05-23 U.S. Philips Corporation Disc-record player suitable for scanning disc of different types
FR2649321A1 (fr) * 1989-07-07 1991-01-11 Inst Nat Sante Rech Med Compositions a base de derives nucleotidiques, leurs procedes de preparation, et leurs utilisations notamment en tant que compositions pharmaceutiques
FR2659554B1 (fr) * 1990-03-16 1994-09-30 Oreal Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant.
AU3462193A (en) * 1993-02-15 1994-08-29 Shield Research Limited Polyalkylcyanoacrylate nanocapsules
ES2152990T3 (es) * 1993-09-09 2001-02-16 Schering Ag Principios activos y microparticulas que contienen gases.
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20030152636A1 (en) * 2000-02-23 2003-08-14 Nanopharm Ag Method of treating cancer
DE60140474D1 (de) 2000-09-08 2009-12-24 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
EP2241309A3 (en) * 2001-07-10 2012-12-26 Corixa Corporation Methods for encapsulation of proteins and adjuants in microspheres
TWI323265B (en) 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
US7993650B2 (en) 2003-07-04 2011-08-09 Affibody Ab Polypeptides having binding affinity for HER2
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
CN1946417A (zh) 2003-12-05 2007-04-11 阿德内克休斯治疗公司 2型血管内皮生长因子受体的抑制剂
DE602005012289D1 (de) 2004-09-14 2009-02-26 Nanodel Technologies Gmbh Abgabevehikel mit nanoteilchen
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
KR101263294B1 (ko) 2006-03-30 2013-06-04 글락소 그룹 리미티드 아밀로이드­베타 펩티드에 대한 항체
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
WO2008149147A2 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery

Also Published As

Publication number Publication date
UY31808A (es) 2009-12-14
CL2009001077A1 (es) 2010-09-24
PE20091829A1 (es) 2009-12-12
EP2271323A2 (en) 2011-01-12
CL2009001080A1 (es) 2010-09-24
AR071633A1 (es) 2010-06-30
UY31810A (es) 2009-12-14
US20110064821A1 (en) 2011-03-17
WO2009135853A3 (en) 2011-05-12
CL2009001081A1 (es) 2010-09-24
UY31807A (es) 2009-12-14
TW201012490A (en) 2010-04-01
CL2009001076A1 (es) 2010-09-24
PE20091882A1 (es) 2009-12-24
AR071634A1 (es) 2010-06-30
AR072668A1 (es) 2010-09-15
WO2009135853A2 (en) 2009-11-12
JP2011522792A (ja) 2011-08-04
UY31809A (es) 2009-12-14
PE20091964A1 (es) 2010-01-09
TW201006495A (en) 2010-02-16
PE20091965A1 (es) 2010-01-09
TW201012488A (en) 2010-04-01
AR072359A1 (es) 2010-08-25
CA2721241A1 (en) 2009-11-12
KR20110010760A (ko) 2011-02-07
KR20110015604A (ko) 2011-02-16
KR20110010758A (ko) 2011-02-07
EP2441447A1 (en) 2012-04-18

Similar Documents

Publication Publication Date Title
TW201012489A (en) Encapsulation of biologically active agents
Ibeanu et al. Injectables and depots to prolong drug action of proteins and peptides
MX2010012136A (es) Encapsulacion de agentes biologicamente activos.
CN108409856B (zh) 结合至肌生成抑制素的基于纤连蛋白的支架结构域蛋白
CN108366968B (zh) 制造蛋白质微粒的组合物和方法
CN109451728A (zh) 抗pacap抗体及其用途
JP2022512541A (ja) Ｐｄ－１系キメラタンパク質を含む併用療法
Douglas et al. Patterned antigens on DNA origami controls the structure and cellular uptake of immune complexes
CN102083423A (zh) 生物活性剂的囊封方法
KR102789747B1 (ko) Prox1 단백질에 중화 활성을 갖는 결합 분자
KR20210118864A (ko) 항-엘라스틴 항체 및 사용 방법
MX2010012137A (es) Encapsulacion de agentes biologicamente activos.
US20250327083A1 (en) Nucleic acid scaffolded artificial immune complexes
TWI914375B (zh) 含有補體路徑抑制物及血管生成抑制物的融合蛋白及其用途
Du et al. Chimeras co-targeting antigens and FcγRIIb trigger degradation of extracellular soluble proteins and pathological aggregates
HK40093655A (zh) 用於长效递送治疗剂的多功能蛋白聚糖(vg1)的透明质酸结合衍生物
HK1251461B (en) Compositions and methods of manufacturing protein microparticles